Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors

Meyerrose T., Olson S., Pontow S., Kalomoiris S., Jung Y., Annett G.

Narrative Review on Tendon Injury, Disc Degeneration, Cardiovascular Disease, Stroke Research, published in Adv Drug Deliv Rev (2010) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Drug Deliv Rev (2010)
Reported sample size
—
Source database
Europe PMC
PMID
20920540
PMCID
PMC3815452
DOI
10.1016/j.addr.2010.09.013
Citations
109

Abstract (original English)

Mesenchymal stem cells (MSC) are a promising tool for cell therapy, either through direct contribution to the repair of bone, tendon and cartilage or as an adjunct therapy through protein production and immune mediation. They are an attractive vehicle for cellular therapies due to a variety of cell intrinsic and environmentally responsive properties. Following transplantation, MSC are capable of systemic migration, are not prone to tumor formation, and appear to tolerize the immune response across donor mismatch. These attributes combine to allow MSC to reside in many different tissue types without disrupting the local microenvironment and, in some cases, responding to the local environment with appropriate protein secretion. We describe work done by our group and others in using human MSC for the sustained in vivo production of supraphysiological levels of cytokines for the support of cotransplanted hematopoietic stem cells and enzymes that are deficient in animal models of lysosomal storage disorders such as MPSVII. In addition, the use of MSC engineered to secrete protein products has been reviewed in several fields of tissue injury repair, including but not limited to revascularization after myocardial infarction, regeneration of intervertebral disc defects and spine therapy, repair of stroke, therapy for epilepsy, skeletal tissue repair, chondrogenesis/knee and joint repai

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsHumansMucopolysaccharidosis VIIImmunologic FactorsCytokinesDrug Delivery SystemsHematopoietic Stem Cell TransplantationMesenchymal Stem Cell TransplantationGenetic EngineeringRegeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research